Search

Hikma v. Amarin Supreme Court Patent Infringement Briefs

Law firm McDonnell Boehnen Hulbert & Berghoff LLP summarizes the parties' opening briefs in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., a Supreme Court case on induced patent infringement by generic drugmakers marketing 'skinny label' products. The Court will decide what conduct—press releases, website statements, or citing sales data—supports a claim of induced infringement under 35 U.S.C. § 271(b) when the generic label carves out the patented indication.